SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-17-148470
Filing Date
2017-04-28
Accepted
2017-04-28 16:41:55
Documents
11
Effectiveness Date
2017-04-28

Document Format Files

Seq Description Document Type Size
1 DEFA14A d376879ddefa14a.htm DEFA14A 32521
2 GRAPHIC g376879txp01a.jpg GRAPHIC 5042
3 GRAPHIC g376879txp01b.jpg GRAPHIC 4722
4 GRAPHIC g376879txp01c.jpg GRAPHIC 5141
5 GRAPHIC g376879txp01d.jpg GRAPHIC 3932
6 GRAPHIC g376879txp02a.jpg GRAPHIC 5128
7 GRAPHIC g376879txp02b.jpg GRAPHIC 1687
8 GRAPHIC g376879txp02c.jpg GRAPHIC 1686
9 GRAPHIC g376879txp02d.jpg GRAPHIC 1573
10 GRAPHIC g376879txp02e.jpg GRAPHIC 5315
11 GRAPHIC g376879txp02f.jpg GRAPHIC 4823
  Complete submission text file 0001193125-17-148470.txt   88906
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

IRS No.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35703 | Film No.: 17796350
SIC: 2834 Pharmaceutical Preparations